In subsequent studies of p53 autoantibody detection in the peripheral blood of breast cancer patients that ended in 2016, the median sensitivity and specificity were 17.5% (4.8-100%) and 98.7% (95-100%), respectively. This evidence concerns the gene TP53 and breast carcinoma.